Visit main University website

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FightMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au
Sort by:
Total Records Found: 2896, showing 100 per page
Biomarker NameUniProt IDPublicationConditionSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
C4BPA P04003 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
C4BPA P04003 Zubiri et al. 2018 ALS fast – ALS slow (early stage) Plasma Up 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
C4BPA P04003 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
C4B_2 E5RGG2 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
C4B P0C0L5 Zhou et al. 2023 SO-ALS – Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
C4B P0C0L5 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
C4B P0C0L5 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
C4A P0C0L4 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
C4A P0C0L4 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
C4A P0C0L4 Xu et al. 2018 ALS – Control Plasma Up 42 ALS, 18 control 61.8 ± 9.6
C3 P01024 Vu et al. 2023 ALS fast – ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
C3 P01024 Berrone et al. 2023 fALS – Control Plasma Down 8 fALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
C3 P01024 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
C3 P01024 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
C3 P01024 Umoh et al. 2018 ALS – Control Frontal cortex Down 19 ALS, 10 control 55 59 10.6
C2 P06681 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
C2 B4DQI1 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
C1S P09871 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
C1S C9IZP8 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
C1RL Q9NZP8 Vu et al. 2023 ALS fast – ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
C1R P00736 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
C1R P00736 Zhou et al. 2023 BO-ALS – Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
C1QTNF5 Q9BXJ0 Zhou et al. 2023 SO-ALS – Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
C1QC P02747 Zhou et al. 2023 SO-ALS – Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
C1QC P02747 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
C1QC P02747 Hayashi et al. 2020 ALS – Control CSF exosome-enriched fractions Down 3 ALS, 3 control 74.3
C1QC P02747 Xu et al. 2018 ALS – Control Plasma Up 42 ALS, 18 control 61.8 ± 9.6
C1QB P02746 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
C1QB P02746 Zhou et al. 2023 SO-ALS – Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
C1QA P02745 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
C1QA P02745 Bereman et al. 2018 ALS – Control CSF Up 33 ALS, 30 control
C1orf123 Q9NWV4 Englen-Lee et al. 2017 ALS – Control Spinal cord (PH & AH) Up 10 ALS, 10 control 57.6 ± 10.9 62.6 ± 10.6
C1GALT1C1 Q96EU7 Oeckl et al. 2020 sALS – Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74)
C19orf70 Q5XKP0 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
C19orf10 Q969H8 Zhou et al. 2023 BO-ALS – Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
C18orf8 Q96DM3 Oeckl et al. 2020 ALS – Control Spinal cord Up 8 ALS, 7 control 59 (52-61) 36 (24-90)
C16orf89 Q6UX73 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
C12orf49 Q9H741 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
BTD P43251 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
BST1 A6NC48 Vassileff et al. 2020 ALS – Control Motor Cortex EVs Down 7 ALS, 3 control
BSG P35613 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
BSCL2 Q96G97 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
BRSK2 Q8IWQ3 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
BRK1 Q8WUW1 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
BOLA2 Q9H3K6 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
BOLA2 Q9H3K6 Seyfried et al. 2018 ALS – Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
BMPR2 Q13873 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
BMP6 P22004 Berrone et al. 2023 fALS – Control Plasma Down 8 fALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
BMP1 P13497 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
BLVRB P30043 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
BLVRB P30043 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
BLMH Q13867 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
BLMH Q13867 Thompson et al. 2020 ALS – Control CSF EVs Down 12 ALS, 5 control 57.8 ±?10.7 60 ±?10.9
BIN1 O00499 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
BIN1 O00499 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
BID P55957 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
BET1 O15155 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
BCX360G3.2 B0V386 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
BCHE P06276 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
BCAP31 P51572 Leoni et al. 2019 BO-ALS – LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS)
BCAP31 P51572 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
BCAP29 B7Z2L0 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
BCAN Q96GW7 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
BCAM P50895 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
BASP1 P80723 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
BASP1 P80723 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
BASP1 P80723 Zubiri et al. 2018 ALS fast – ALS slow (early stage) Plasma Up 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
BAMBI Q13145 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
BAIAP2 Q9UQB8 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
B4GALT1 P15291 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
B4GALNT4 Q76KP1 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
B4GALNT1 Q00973 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
B3GNT9 Q6UX72 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
B3GNT8 Q7Z7M8 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
B3GNT8 Q7Z7M8 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
B3GNT2 Q9NY97 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
B2M P61769 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
B2M P61769 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
AZGP1 P25311 Vu et al. 2023 ALS fast – ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
AZGP1 P25311 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
AVIL O75366 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
AUH Q13825 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
AUH Q13825 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
ATXN10 Q9UBB4 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
ATRN O75882 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
ATP8A2 Q9NTI2 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
ATP8A1 Q9Y2Q0 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
ATP6V1G2 O95670 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
ATP6V1G2 O95670 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
ATP6V1F Q16864 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
ATP6V1F Q16864 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
ATP6V1E1 P36543 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
ATP6V1D Q9Y5K8 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
ATP6V1C1 P21283 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
ATP6V1B2 P21281 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
ATP6V1B2 P21281 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
ATP6V0D1 P61421 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
ATP6V0C P27449 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
ATP6V0A1 Q93050 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
ATP6AP2 A0A1B0GVW0 Andrés-Benito et al. 2020 ALS – Control CSF Up 15 ALS, 15 control 61 ± 10.8